Taxotere has demonstrated significant antitumor activity in these difficult to treat patient populations. A premedication regimen consisting of corticosteroids is recommended as the standard to delay the onset and reduce the incidence and severity of certain side effects. Taxotere is currently available for treatment of advanced breast and non-small cell lung cancer in Mexico and South Africa. Taxotere belongs to a class of anti-cancer agents called taxoids. Taxotere inhibits cancer cell division by acting on the cell's internal skeleton, which is made up of microtubules.
Microtubules assemble and disassemble during the cell cycle.
Taxotere promotes the assembly and blocks the disassembly, thus preventing cancer cells from dividing. This action leads to cancer cell death. RPR Canada expects to make the drug available within the next eight weeks. A future announcement will provide more detail. Please contact us with any comments, problems or bugs.